South Africa Pharmacogenetic Testing in Psychiatry depression Market to 2032

Overview

The South Africa Pharmacogenetic Testing in Psychiatry depression Market is expected to reach a 25.36 USD Billion by 2032 and is projected to grow at a CAGR of 13.97% from 2025 to 2032.

Revenue, 2024 (USD Billion)
12.80
Forecast, 2032 (USD Billion)
25.36
CAGR, 2024 - 2032
13.97%
Report Coverage
South Africa

South Africa Pharmacogenetic Testing in Psychiatry depression Market 2018-2032 USD Billion

South Africa Pharmacogenetic Testing in Psychiatry depression Market, Key Findings (2025-2032)

Market Growth and Projections:

  • Market Size (2024): 12.80 USD Billion
  • Projected Market Size (2032): 25.36 USD Billion
  • CAGR (2025-2032): 13.97%

Key Findings of South Africa Pharmacogenetic Testing in Psychiatry depression Market

  • The South Africa Pharmacogenetic Testing in Psychiatry depression Market was valued at 12.80 USD Billion in 2024.
  • The South Africa Pharmacogenetic Testing in Psychiatry depression Market is likely to grow at a CAGR of 13.97% during the forecast period of 2024 to 2032.
  • In 2024, the Largest segment Saliva in Sample Segment accounted for the largest share of the market with a revenue of 9.69 USD Billion
  • The fastest growing segment CYP2C19 in Genes Segment grew Fastest with a CAGR of 19.29% during the forecast period from 2024 to 2032.

South Africa Pharmacogenetic Testing in Psychiatry depression Market Scope

South Africa Pharmacogenetic Testing in Psychiatry depression Market Segmentation & Scope
Distribution Channel
  • Direct-To-Customer Services
  • Mail-Order Pharmacies
  • Hospital Pharmacies
  • Retail Pharmacies
End User
  • Others
  • Research Centres And Academic Institutes
  • Healthcare Providers
  • Pharmaceutical & Biotechnology Companies
Type
  • Array-Based Tests
  • Whole Genome Sequencing
Application
  • Clinical Practice
  • Drug Development
Sample
  • Blood
  • Saliva
Genes
  • COMT
  • MTHFR
  • SLC6A4
  • CYP3A4
  • HLA-A
  • HTR2A/C
  • Others
  • HLA-B
  • CYP2D6
  • CYP2C9 AND VKORC1
  • CYP2C19
Drug Type
  • Vitamins/Nutraceuticals
  • Recreational Drugs
  • Over-The-Counter Medications
  • Prescription Drugs

South Africa Pharmacogenetic Testing in Psychiatry depression Market Data Coverage Insights

Study Period 2024-2032
Base Year 2020
Unit Revenue in USD Billion
Market Value in 2024 12.80 USD Billion
Market Value in 2032 25.36 USD Billion
CAGR (2025-2032) 13.97%
Historic Data 2016-2023
Market Segments Covered Distribution Channel,End User,Type,Application,Sample,Genes,Drug Type

Regional Insights:

  • Leading Market (2024-2032): South Africa, leading in terms of revenue 12.80 USD Billion in 2024
    • Key Country: South Africa, leading in terms of revenue with value of 12.80 USD Billion in 2024.

Segments and Scope

  • South Africa Pharmacogenetic Testing in Psychiatry depression Market to 2032, By Distribution Channel
    • Retail Pharmacies is the largest segment in South Africa Pharmacogenetic Testing in Psychiatry depression Market to 2032 with a revenue of 5.27 USD Billion in the year 2024.
    • Hospital Pharmacies is the Fastest growing segment in South Africa Pharmacogenetic Testing in Psychiatry depression Market to 2032 with a Growth rate of 12.91 % in forecast period 2025-2032.
  • South Africa Pharmacogenetic Testing in Psychiatry depression Market to 2032, By End User
    • Pharmaceutical & Biotechnology Companies is the largest segment in South Africa Pharmacogenetic Testing in Psychiatry depression Market to 2032 with a revenue of 5.47 USD Billion in the year 2024.
    • Pharmaceutical & Biotechnology Companies is the Fastest growing segment in South Africa Pharmacogenetic Testing in Psychiatry depression Market to 2032 with a Growth rate of 15.14 % in forecast period 2025-2032.
  • South Africa Pharmacogenetic Testing in Psychiatry depression Market to 2032, By Type
    • Whole Genome Sequencing is the largest segment in South Africa Pharmacogenetic Testing in Psychiatry depression Market to 2032 with a revenue of 8.10 USD Billion in the year 2024.
    • Whole Genome Sequencing is the Fastest growing segment in South Africa Pharmacogenetic Testing in Psychiatry depression Market to 2032 with a Growth rate of 14.49 % in forecast period 2025-2032.
  • South Africa Pharmacogenetic Testing in Psychiatry depression Market to 2032, By Application
    • Drug Development is the largest segment in South Africa Pharmacogenetic Testing in Psychiatry depression Market to 2032 with a revenue of 6.88 USD Billion in the year 2024.
    • Drug Development is the Fastest growing segment in South Africa Pharmacogenetic Testing in Psychiatry depression Market to 2032 with a Growth rate of 14.72 % in forecast period 2025-2032.
  • South Africa Pharmacogenetic Testing in Psychiatry depression Market to 2032, By Sample
    • Saliva is the largest segment in South Africa Pharmacogenetic Testing in Psychiatry depression Market to 2032 with a revenue of 9.69 USD Billion in the year 2024.
    • Saliva is the Fastest growing segment in South Africa Pharmacogenetic Testing in Psychiatry depression Market to 2032 with a Growth rate of 14.30 % in forecast period 2025-2032.
  • South Africa Pharmacogenetic Testing in Psychiatry depression Market to 2032, By Genes
    • CYP2C19 is the largest segment in South Africa Pharmacogenetic Testing in Psychiatry depression Market to 2032 with a revenue of 3.13 USD Billion in the year 2024.
    • CYP2C19 is the Fastest growing segment in South Africa Pharmacogenetic Testing in Psychiatry depression Market to 2032 with a Growth rate of 19.29 % in forecast period 2025-2032.
  • South Africa Pharmacogenetic Testing in Psychiatry depression Market to 2032, By Drug Type
    • Prescription Drugs is the largest segment in South Africa Pharmacogenetic Testing in Psychiatry depression Market to 2032 with a revenue of 6.21 USD Billion in the year 2024.
    • Recreational Drugs is the Fastest growing segment in South Africa Pharmacogenetic Testing in Psychiatry depression Market to 2032 with a Growth rate of 14.29 % in forecast period 2025-2032.

South Africa Pharmacogenetic Testing in Psychiatry depression Market Company Share Analysis

 
Company Name Company Share Analysis
Millennium Health
Myriad Genetics, Inc.
PerkinElmer Inc.
Illumina, Inc.
Thermo Fisher Scientific Inc.
South Africa Pharmacogenetic Testing in Psychiatry depression Market Company Share Analysis

South Africa Pharmacogenetic Testing in Psychiatry depression Market Geographical Sales Distribution, 2018-2032 USD Billion

South Africa Pharmacogenetic Testing in Psychiatry depression Market Geographical Sales Distribution, 2018-2032 USD Billion

South Africa Pharmacogenetic Testing in Psychiatry depression Market Company Profiling

South Africa Pharmacogenetic Testing in Psychiatry depression Market Company Profiling
Frequently Asked Questions
The South Africa Pharmacogenetic Testing in Psychiatry depression Market is segmented based on Segmentation Distribution Channel,End User,Type,Application,Sample,Genes,Drug Type.
South Africa Pharmacogenetic Testing in Psychiatry depression Market was valued at USD 12.80(Revenue in USD Billion) in 2020.
South Africa Pharmacogenetic Testing in Psychiatry depression Market is projected to grow at a CAGR of 13.97% during the forecast period of 2024 to 2032.
The Saliva segment is expected to dominate the South Africa Pharmacogenetic Testing in Psychiatry depression Market, holding a largest market share of 9.69 USD Billion in 2024

South Africa Pharmacogenetic Testing in Psychiatry depression Market Scope

South Africa Pharmacogenetic Testing in Psychiatry depression Market Segmentation & Scope
Distribution Channel
  • Direct-To-Customer Services
  • Mail-Order Pharmacies
  • Hospital Pharmacies
  • Retail Pharmacies
End User
  • Others
  • Research Centres And Academic Institutes
  • Healthcare Providers
  • Pharmaceutical & Biotechnology Companies
Type
  • Array-Based Tests
  • Whole Genome Sequencing
Application
  • Clinical Practice
  • Drug Development
Sample
  • Blood
  • Saliva
Genes
  • COMT
  • MTHFR
  • SLC6A4
  • CYP3A4
  • HLA-A
  • HTR2A/C
  • Others
  • HLA-B
  • CYP2D6
  • CYP2C9 AND VKORC1
  • CYP2C19
Drug Type
  • Vitamins/Nutraceuticals
  • Recreational Drugs
  • Over-The-Counter Medications
  • Prescription Drugs
Frequently Asked Questions
The South Africa Pharmacogenetic Testing in Psychiatry depression Market is segmented based on Segmentation Distribution Channel,End User,Type,Application,Sample,Genes,Drug Type.
South Africa Pharmacogenetic Testing in Psychiatry depression Market was valued at USD 12.80(Revenue in USD Billion) in 2020.
South Africa Pharmacogenetic Testing in Psychiatry depression Market is projected to grow at a CAGR of 13.97% during the forecast period of 2024 to 2032.
The estimated market value of the South Africa Pharmacogenetic Testing in Psychiatry depression Market for final year is USD 25.36 (USD Billion).

South Africa Pharmacogenetic Testing in Psychiatry depression Market Company Profiling

South Africa Pharmacogenetic Testing in Psychiatry depression Market Company Profiling
Frequently Asked Questions
The South Africa Pharmacogenetic Testing in Psychiatry depression Market is segmented based on Segmentation Distribution Channel,End User,Type,Application,Sample,Genes,Drug Type.
South Africa Pharmacogenetic Testing in Psychiatry depression Market was valued at USD 12.80(Revenue in USD Billion) in 2020.
South Africa Pharmacogenetic Testing in Psychiatry depression Market is projected to grow at a CAGR of 13.97% during the forecast period of 2024 to 2032.
The estimated market value of the South Africa Pharmacogenetic Testing in Psychiatry depression Market for final year is USD 25.36 (USD Billion).